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Background: Rapid diagnostic tests (RDTs) are immune chromatographic tests targeting antigens of one or more
Plasmodium species and offer the potential to extend accurate malaria diagnosis in endemic areas. In this study,
the performance of Plasmodium falciparum-specific histidine-rich protein-2 (PfHRP-2) RDT in the detection of
asymptomatic carriers from a hyperendemic region of Burkina Faso was compared with microscopy to gain further
insight on its relevance in community-based interventions.
Methods: The performance of HRP-2 test was evaluated in terms of sensitivity, specificity, positive and negative
predictive values, discordant values, likelihood ratios, accuracy, and precision using microscopy as the ‘gold
standard’. This analysis was carried out in a controlled, parallel, cluster-randomized (18 clusters; 1:1) study in children
and adults. The effect of systematic treatment of P. falciparum asymptomatic carriers during three consecutive
monthly community screening campaigns on the incidence of symptomatic malaria episodes over a 12-month
period was compared with no treatment of asymptomatic carriers.
Results: Sensitivity of HRP-2 test in asymptomatic carriers was higher in campaign 1 (92.4%) when compared to
campaign 2 (84.0%) and campaign 3 (77.8%). The sensitivity of HRP-2 test increased as parasite density increased
across all the age groups. Highest sensitivity (≥97.0%) was recorded at parasite densities of 1,000-4,999/μl, except
for children aged 10 to 14 years. The specificity of HRP-2 test was comparable across age groups and highest in
campaign 3 (95.9%). The negative predictive values were high across the three campaigns (≥92.7%) while the
positive predictive values ranged from 23.2 to 73.8%. False-positive and false-negative rates were high in campaign
1 and campaign 3, respectively.
Conclusion: The performance of HRP-2 test in detecting asymptomatic carriers of P. falciparum varied by age and
parasite density. Although the use of HRP-2 test is beneficial for the diagnosis of acute malaria, its low sensitivity in
screening asymptomatic carriers may limit its utility in pre-elimination interventional settings. The use of a practical
and more sensitive test such as loop-mediated isothermal amplification in combination with a cost effective HRP-2
test may be worth exploring in such settings.
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Both microscopy and rapid diagnostic tests (RDTs) have
been recommended by the World Health Organization
(WHO) for diagnosis of malaria. The choice between the
two methods varies according to available skills, patient-
case load and local setting. Microscopy is the reference
method for malaria diagnosis and can be used to identify
species, parasite density and response to anti-malarial
therapy. However, a major drawback of this tool is its re-
quirement of well-trained, skilled staff and an energy
source to power the microscope [1].
There are currently over 200 RDTs produced by 60
manufacturers, which detect Plasmodium falciparum,
Plasmodium vivax or all human Plasmodium species [2].
Target antigens for P. falciparum detection are P.
falciparum-specific histidine-rich protein-2 (PfHRP-2)
and P. falciparum-specific parasite lactate dehydrogen-
ase (Pf-pLDH). For P. vivax detection, the target antigen
is P. vivax-specific parasite lactate dehydrogenase (Pv-
pLDH). For all human Plasmodium species, pan-pLDH
and aldolase can be detected by RDTs [3]. In field trials,
malaria RDTs have demonstrated ≥90% sensitivity and
specificity for P. falciparum infection with parasite dens-
ities of ≥200 parasites/μl [4]. HRP-2 tests are highly sen-
sitive for P. falciparum infections at parasite densities
above 100–200 parasites/μl, but have limited reliability
at lower parasite densities [4]. Detection of P. vivax var-
ies at densities of 100–200 parasites/μl and higher, de-
pending on the RDT product and target antigen [5]. The
specificity of HRP-2 tests raises concerns in areas of in-
tense malaria transmission due to slow clearance and
persistence of HRP-2 antigens in the bloodstream for
several weeks due to prior infections [3,6-8]. Another re-
cently reported concern was a high rate of false-negative
results in asymptomatic carriers of P. falciparum. False-
negative results were reported only in individuals with
asymptomatic infections, suggesting that parasites that
fail to produce HRP-2 can cause patent bloodstream in-
fections [9].
Asymptomatic carriers are individuals who are in-
fected with plasmodial asexual forms, with or without
gametocytes, but do not present any clinical symptoms.
These individuals are a concern because they serve as
reservoirs of parasites including gametocytes that are
difficult to detect, and diagnosis presents challenges due
to lack of distinct clinical manifestations. There is a posi-
tive correlation between number of asymptomatic car-
riers and high transmission, which may be due to
exposure related immunity [10].
The aim of this paper is to report HRP-2 based RDT
results from a recent cluster-randomized trial in Burkina
Faso, which investigated the systematic, community-
wide screening and treatment of asymptomatic carriers
of P. falciparum with artemether-lumefantrine (AL). Themain outcomes of the study have already been published
[11]; however, the data on the HRP-2 test performance
provide an opportunity to gain further insight on its
relevance in detection of P. falciparum asymptomatic
carriers in such community-based interventions.Methods
Approach for screening of asymptomatic carriers
This analysis was carried out in a controlled, parallel,
cluster-randomized study to evaluate the performance of
HRP-2 based RDT in comparison with microscopy in
detection of P. falciparum asymptomatic carriers in the
health district of Saponé, Burkina Faso, which is an area
with marked seasonal P. falciparum malaria transmis-
sion from June to November. The incidence of symp-
tomatic malaria episodes in children (<5 years) and
adults over a 12-month period was compared with
asymptomatic carriers who were not treated. A total of
18 clusters, each comprising one village, were selected to
participate in this trial, and were randomized in a 1:1 ra-
tio to either the intervention or control arm.
Prior to the transmission (rainy) season, screening and
treatment of asymptomatic carriers took place and all in-
habitants of the intervention arm and 40% of inhabitants
of the control arm participated in three community
screening campaigns (campaign 1 to 3), which were ap-
proximately one month apart between January and April
2011. During each screening campaign, subjects in the
intervention arm were home visited and screened for P.
falciparum asexual forms using HRP-2 test. Blood
smears for delayed microscopy readings were simultan-
eously collected. In the control arm, only blood smears
for delayed microscopy readings were obtained. RDT-
positive individuals from the intervention arm received
treatment with AL (20 mg artemether and 120 mg
lumefantrine [Coartem®, Novartis Pharma AG, Basel,
Switzerland]) or AL dispersible, twice daily for three
consecutive days. As inherent to the study design, results
reported here are only from the intervention arm where
both HRP-2 based RDT and microscopy data were con-
comitantly collected.Rapid diagnostic test
First Response® Malaria Ag, (Premier Medical Corp Ltd.,
Nani-Daman, India) was used. This is a HRP-2 test recom-
mended by WHO for its performance at low parasite
densities, low false-positive rate, and high heat stability
[12]. RDT stock was stored in an air-conditioned room
with ambient temperature and humidity recorded twice
daily at the Centre National de Recherche et de Formation
sur le Paludisme (CNRFP). During the screening cam-
paigns, in the absence of electricity, test kits were kept in
cold boxes within the local health facility to which the
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twice daily (morning and afternoon) by the study nurses.
Diagnostic microscopy
Blood films were air-dried and Giemsa-stained for exam-
ination by a light microscope fitted with 100 × oil
immersion lens at a single laboratory. At least 200 thick
film fields were examined before a slide was declared
negative. If Plasmodium asexual forms were found, a
total of 200 thick film fields were screened for Plasmo-
dium species other than P. falciparum. If P. falciparum
was present, a count of asexual forms against leukocytes
was made using a tally counter. Counting was conducted
based on at least 200 leukocytes in consistence with
WHO standards. If less than 10 parasites were identified
from the 200 leukocyte screened, the count was
extended to 1,000 leukocytes. On the other hand, if P.
falciparum gametocytes were seen, a gametocyte count
was performed against 1,000 leukocytes. All slides were
read by two independent microscopists. If the ratio of
densities from the first two readings was >1.5 or < 0.67,
or if less than 30 parasites were counted with an abso-
lute difference of more than 10 in the number of para-
sites, the slide was evaluated by a third microscopist.
The definitive result was the mean of the parasite dens-
ity of the two most concordant readings. Microscopist
competency was evaluated through two external quality
control (EQC) programmes. The first EQC was carried
out by the College of American Pathology proficiency
testing and included a set of five slides provided to each
microscopist for reading; three rounds of proficiency
testing were conducted per year. The second EQC was
performed by WHO (National Institute for Communic-
able Diseases) and involved the reading of a set of 20
slides every quarter by each microscopist. Only those
with a score of at least 80%, graded as ‘competent’, were
involved in the reading of trial participants’ slides.
Statistical methods
Data were entered into an electronic web-based case re-
port form and were analysed using SAS® version 9.2 on
UNIX according to a pre-defined analytical plan. The
study sample was categorized into four age groups: zero to
four years, five to nine years, 10 to 14 years, and ≥15 years.
Six categories of parasite densities were considered for
subjects with parasitaemia: 0–99 parasites/μl, 100–249
parasites/μl, 250–499 parasites/μl, 500–999 parasites/μl,
1,000-4,999 parasites/μl, and ≥5,000 parasites/μl.
Each HRP-2 result was categorized as true positive
(TP), true negative (TN), false positive (FP), or false
negative (FN). Sensitivity was calculated as TP/(TP +
FN) and specificity as TN/(TN + FP). Positive predictive
value (PPV) was defined as TP/(TP + FP) and negative
predictive value (NPV) as TN/(TN + FN). False-positiverate was calculated as FP/(FP + TN) and false-negative
rate was calculated as 1-(TN/[TN + FP]). Positive likeli-
hood ratio was defined as the probability of a positive
test result in patients with the disease divided by the
probability of a positive test result in patients without
the disease (i.e., sensitivity/[1 − specificity]), and negative
likelihood ratio as the probability of a negative test result
in patients with the disease divided by the probability of
a negative test result in patients without the disease (i.e.,
[1 − sensitivity]/specificity). Accuracy, the proportion of
all tests that yielded a correct result, was defined as (TP +
TN)/(TP + TN+ FP + FN). Cohen’s Kappa value, the quan-
titative measure of the magnitude of agreement between
two tests was calculated. The test performance was evalu-
ated across the three screening campaigns and for categor-
ies of age and parasite density. Geometric mean parasite
density by age group was also reported.
Ethical aspects
The clinical trial protocol and informed consent forms
were approved by the CNRFP Institutional Review Board
and by the National Ethical Committee for Health
Research of Burkina Faso. Prior to study initiation, a
community meeting was held in each of the selected
clusters to discuss the study objectives with the commu-
nities. The freedom of each individual household and
household member to decide on study participation was
discussed to minimize the potential influence of key
opinion leaders in each cluster. Individual informed con-
sent was obtained from each participant during a visit to
the household prior to any study procedure.
Results
Of 14,075 subjects assessed for eligibility, a total of 6,817
subjects in the intervention arm and 7,258 subjects in
the control arm were recruited and enrolled in the study
(Figure 1). The intervention and control arms were simi-
lar in terms of demographic characteristics with the ex-
ception of ethnicity; the intervention arm had a higher
proportion of Fulani. The primary outcomes of this
study were reported by Tiono et al. [11].
A total of 17,505 samples from 6,817 subjects in the
intervention arm were examined by microscopy and
HRP-2 test across the three campaigns (Table 1). About
47% of the participants were women and their mean age
at baseline was 24.4 years.
Overall, 5,563 (31.8%) samples were detected to be
positive using microscopy (Table 1). The prevalence of
P. falciparum infection as detected by microscopy was
highest among subjects aged ≥15 years, followed by five
to nine year olds and 10 to 14 year olds. Using HRP-2
test, 4,314 (24.6%) samples were detected to be positive
for P. falciparum (Table 1). The prevalence of P. falcip-
arum infection by age as detected by HRP-2 test
Figure 1 Consort chart. 1RDT was not done for subjects in the control arm and participants were excluded from the analysis. 2Not included in
analysis as assessment was done after third campaign.
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but in campaigns 2 and 3, prevalence was highest among
subjects aged ≥15 years, followed by <5 year olds and 10
to 14 year olds. The prevalence of P. falciparum infec-
tion by density ranged from 8.2 to 28.3% in campaign 1,
4.4 to 34.6% in campaign 2, and 4.4 to 33.0% in cam-
paign 3 (Table 1). Across the three campaigns, the geo-
metric mean P. falciparum density decreased with
increasing age; it was highest in children <5 years of age
(Table 1).
Sensitivity of HRP-2 test in asymptomatic carriers was
higher in campaign 1 when compared to campaign 2
and campaign 3 (Table 2 and Figure 2). Specificity of
HRP-2 test was highest in campaign 3 (Table 2 and
Figure 2). Negative predictive values were high across
the three campaigns, while positive predictive values
ranged from 23.2 to 73.8%. An overview of the discord-
ant results (i.e., either a false-positive or false-negative
HRP-2 compared with microscopy) is given in Table 2.
False-positive and false-negative rates were high in cam-
paign 1 and campaign 3, respectively. Positive likelihood
ratio was highest in campaign 3 followed by campaign 2
and campaign 1. Negative likelihood ratio was lowest in
campaign 1, followed by campaign 2 and campaign 3.
The proportion of all true HRP-2 test results yielded an
accuracy of 0.82, 0.88, and 0.95 in campaigns 1, 2 and 3,
respectively. The agreement between the two techniques,
HRP-2 test and microscopy, was highest in campaign 1.
Generally, the sensitivity of HRP-2 test increased as
parasite density increased across all the age groups
(Table 3 and Figure 2). At parasite densities of 1,000-4,999/μl, HRP-2 test recorded the highest sensitivity, ex-
cept for children aged 10 to 14 years.
Discussion
This paper describes the performance of HRP-2 test in
comparison with microscopy in the detection of asymp-
tomatic carriers in community-wide screening and treat-
ment campaigns from a hyperendemic region of Burkina
Faso. The findings provide evidence that while HRP-2
test might be a convenient diagnostic tool in a similar
community based intervention with highly demanding
logistics, it has obvious limitations that could jeopardize
the success of the intervention.
What lessons were learned from this analysis?
Two main lessons could be drawn from the results of
this trial. The first lesson is that HRP-2 test might not
be suitable to use across all age groups in screening
campaigns for asymptomatic carriers. Indeed, the test
sensitivity decreased with age. This finding is consistent
with previous reports showing that the proportion of in-
fected individuals with low parasite densities increased
with age, most likely due to age acquired immunity
[13-15]. Thus, the age-dependent immune status might
have lowered the HRP-2 test sensitivity [16]. This re-
duced sensitivity might have a serious impact on the ef-
fectiveness of mass screening and treatment (MSAT)
strategies aiming to interrupt transmission. Indeed, as
shown in a previous study, although gametocytes are
most commonly detected in children, the proportion of
asexual parasites that will develop into gametocytes may
Table 1 Characteristics of study participants across three
screening campaigns
Campaign 1 Campaign 2 Campaign 3
Number of participants 5,633 5,718 6,154
Mean age (years) 24.4 23.9 23.0
Number (%) of females 2,617 (46.5) 2,664 (46.6) 2,863 (46.5)
Prevalence of
P. falciparum infection
(by microscopy), n (%)
0- <5 689 (12.2) 205 (3.6) 193 (3.1)
5-9 971 (17.2) 318 (5.6) 271 (4.4)
10-14 841 (14.9) 253 (4.4) 218 (3.5)
≥15 1,080 (19.1) 294 (5.1) 230 (3.7)
Overall 3,581 (63.6) 1,070 (18.7) 912 (14.8)
Prevalence of
P. falciparum infection
(by HRP-2 test), n (%)
0- <5 606 (10.8) 238 (4.1) 86 (1.4)
5-9 734 (13.0) 175 (3.0) 52 (0.8)
10-14 674 (12.0) 114 (2.0) 49 (0.8)
≥15 1,060 (18.8) 336 (5.9) 190 (3.1)





1-99 798 (22.3) 272 (25.4) 258 (28.3)
100-499 1,013 (28.3) 370 (34.6) 301 (33.0)
500-999 599 (16.7) 182 (17.0) 148 (16.2)
1,000-4,999 877 (24.5) 199 (18.6) 165 (18.1)
≥5,000 294 (8.2) 47 (4.4) 40 (4.4)
Overall 3,581 (100.0) 1,070 (100.0) 912 (100.0)
Geometric mean
P. falciparum density
in positives by age
(parasites/μl)
0- <5 1,348 702 756
5-9 795 482 387
10-14 406 273 241
≥15 168 127 111
Overall 470 315 291
Age was considered at cluster initiation. Percentages in prevalence subgroups
are based on the total number of subjects in the respective subgroup.
Table 2 Overall performance of HRP-2 test in asymptomatic
carriers across three screening campaigns
Campaign 1 Campaign 2 Campaign 3
Sensitivity, %
(95% CI)
92.4 (91.4, 93.5) 84.0 (79.3, 88.6) 77.8 (71.5, 84.0)
Specificity, %
(95% CI)
74.6 (73.1, 76.1) 87.9 (87.0, 88.7) 95.9 (95.4, 96.4)
Positive predictive
value, % (95% CI)
73.8 (72.2, 75.3) 23.2 (20.3, 26.0) 35.4 (30.5, 40.2)
Negative predictive
value, % (95% CI)
92.7 (91.7, 93.7) 99.2 (99.0, 99.5) 99.3 (99.1, 99.5)
False-positive rate 0.25 0.12 0.04







Accuracy 0.82 0.88 0.95
Kappa, % (95% CI) 65.2 (63.2, 67.1) 31.9 (28.3, 35.4) 46.6 (41.4, 51.8)
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tribution of adults for human infectious reservoir of
malaria [17]. Another study that evaluated the contribu-
tion of different age groups to the human infectious res-
ervoir found that adults may be responsible for 28 to
38% of mosquito infections [18]. This proportion could
be even larger if differences in body size and exposureindex to mosquitoes between adults and children were
considered [19]. In total, failing to detect asexual para-
sites in adults in MSAT studies would thus highlight the
missed opportunity in clearing the probably most im-
portant reservoir of parasites.
Overall, the HRP-2 test specificity was low and in-
creased with age. Difference was only statistically signifi-
cant when comparison was done between zero to
<5 years and both 10 to 14 and ≥15 years age groups.
Previous studies showed that recently treated infections
may lead to false-positive results [3,6-8]. The delayed
clearance and persistence of HRP-2 antigen in the blood,
even after complete eradication of parasites, can limit
the utility of the test [6,14,20]. The difference between
age groups could be explained by the difference in inci-
dence of clinical malaria episodes. Younger children are
more prone to developing clinical symptoms and getting
treated. Hence, the likelihood of detecting HRP-2 antige-
naemia post treatment is high in this subpopulation. In
theory, there is no potential impact of this low specificity
on the effectiveness of the MSAT intervention. However,
frequent false-positive findings can lead to unnecessary
treatment [20].
The second important lesson from this trial is that
HRP-2 might not be sufficient as a single diagnostic
method in MSAT involving multiple screening cam-
paigns. While the sensitivity and positive predictive
values were high at the first campaign, a significant de-
crease below recommended standard by WHO [21] was
observed during the next two campaigns. This trend was
similar to the one observed for the prevalence of infec-
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Figure 2 Prevalence of Plasmodium falciparum infection, parasite count and rapid diagnostic test accuracy (sensitivity and specificity)
according to screening campaigns.
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harboured parasites at low densities that were below de-
tection limit of the HRP-2 test. The proportion of subjects
with parasite count <500 parasites/μl rose from 50.6% at
first campaign to ~60% at second and third campaigns.
This is supported by similar findings in Solomon Islands
(low transmission setting) where a study conducted
showed that a large proportion of asymptomatic P. falcip-
arum and P. vivax infections had low and submicroscopic
parasite densities that were not detected by RDT. The re-
sults suggested that the detection limit of the ICT combo
kit was ~100 parasites/μl for P. falciparum and >300 para-
sites/μl for P. vivax [13]. Another study evaluated the per-
formance of Optimal® rapid malaria test compared to
expert microscopy as a tool for detecting asymptomatic
malaria in an area of Thailand that is endemic for both P.
falciparum and P. vivax. The low sensitivity of Optimal®
rapid malaria test along with poor assay specificity and
high number of false-positive cases in individuals with
parasite densities <500/μl, suggested that the majority of
malaria cases may not have been accurately detected dur-
ing a similar surveillance programme [22].
Contrary to the sensitivity trend, the specificity and
negative predictive values increased as the screening
campaigns progressed. This provides evidence that the
use of HRP-2 test has made it possible to comply with
the overall goal of the MSAT intervention, which was to
treat only those carrying malaria parasites, therefore
minimizing overuse of drugs in non-parasitaemic sub-
jects, and in turn reducing drug pressure.
Are there alternatives to RDTs in such trials?
Microscopy is widely accepted as a gold standard labora-
tory method. However, examining blood smears withhigh quality and accuracy requires extensive experience
and training [23]. Furthermore, the use of microscopy
may not be feasible in remote areas where malaria is
prevalent [24] and results may not be readily available
for treatment decision making. The experience in this
trial suggests that a point-of-care malaria diagnostic tool
is the best option to minimize logistical hurdles and en-
sure good coverage of the population. To overcome the
limitations of detecting infections of lower density by
microscopy and RDT, molecular diagnostic methods,
such as polymerase chain reaction (PCR) have been de-
veloped. Studies using PCR in low transmission settings
have revealed a high proportion of low-density parasitae-
mias and asymptomatic carriers that were not detected
by RDT or microscopy [5,13,25,26].
Loop mediated isothermal amplification (LAMP) is an
innovative gene amplification technique emerging as a
simple rapid diagnostic tool for early detection and iden-
tification of microbial diseases. There is evidence that
LAMP may be a fast, simple, and cost-effective diagnos-
tic approach in detecting malaria parasites. LAMP uses
DNA polymerase and amplifies a target DNA sequence
with high sensitivity and specificity under isothermal
conditions. Several studies have evaluated the sensitivity
and specificity of LAMP for the detection and differenti-
ation of Plasmodium species for human malaria. An ad-
vantage of LAMP is that results can be analysed with
the naked eye based on turbidity or the use of fluores-
cent dyes [27]. Studies have also shown that LAMP is
superior to expert microscopy, has diagnostic accuracy
similar to PCR, and can produce results in a shorter
time [28-30]. Current results and further development of
LAMP may provide the possibility of its future use in
the diagnosis of malaria.
Table 3 Performance of HRP-2 test in asymptomatic carriers by age and parasite density
Age group (years) Parasite density (/μl) N Positive Negative Sensitivity % (95% CI) Specificity % (95% CI)
0- <5 0-99 2,663 433 2,230 74.6 (64.5, 84.8)
100-499 90 83 7 92.2 (86.7, 97.8)
500-999 86 85 1 98.8 (96.6, 100)
1,000-4,999 211 209 2 99.1 (97.7, 100)
≥5,000 117 114 3 97.4 (94.6, 100)
Overall 3,167 924 2,243 94.6 (92.8, 96.5) 85.3 (84.0, 86.7)
5-9 0-99 2,147 327 1,820 84.0 (75.7, 92.3)
100-499 184 171 13 92.9 (89.2, 96.6)
500-999 145 143 2 98.6 (96.7, 100)
1,000-4,999 246 245 1 99.6 (98.8, 100)
≥5,000 69 68 1 98.6 (95.7, 100)
Overall 2,791 954 1,837 96.0 (94.5, 97.4) 87.3 (85.8, 88.7)
10-14 0-99 2,124 346 1,778 85.5 (79.8, 91.2)
100-499 215 206 9 95.8 (93.1, 98.5)
500-999 104 103 1 99.0 (97.2, 100)
1,000-4,999 145 144 1 99.3 (98.0, 100)
≥5,000 31 31 100 (100, 100)
Overall 2,619 830 1,789 95.0 (93.3, 96.7) 88.8 (87.4, 90.2)
≥15 0-99 8,287 1,129 7,158 73.1 (68.8, 77.5)
100-499 310 265 45 85.5 (81.6, 89.4)
500-999 107 101 6 94.4 (90.0, 98.8)
1,000-4,999 66 64 2 97.0 (92.8, 100)
≥5,000 17 10 7 58.8 (35.4, 82.2)
Overall 8,787 1,569 7,218 81.4 (78.8, 83.9) 89.4 (88.7, 90.1)
N = number of subjects for whom RDT and microscopy results were available.
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interventions?
RDTs are still appealing since they are easy to use and
can help overcome the challenges of microscopy in
field-based trials. However, low sensitivity of RDTs in
screening asymptomatic carriers limits their utility as
single diagnostic tool in interventions targeting the
parasite reservoirs (i.e., MSAT). While LAMP may be
an option, given its ease of use in the field and diagnos-
tic accuracy, its role in MSAT trials needs to be ex-
plored especially in settings where prevalence of malaria
is high. It might not be cost effective to use this tool as
stand-alone in such settings. Rational combinations
with RDTs need to be explored. One possible scenario
would be to use both RDT and LAMP in the first
screening and treatment campaign, where RDT is used
in children and LAMP in individuals ≥15 years. This ap-
proach adds cost and complexity to the trial implemen-
tation, but could help to prevent spread of the infection
(by those who were not detected by RDT) in the interval
before the next campaign. In subsequent campaigns,using LAMP in newcomers to the area or in the whole
population, based on malaria transmission dynamics,
may be targeted.
In areas with reports of high RDT sensitivity that is
consistent across ages, exclusive use of RDT at the first
campaign could be a better option to minimize cost.
LAMP should be preferred for subsequent campaigns.
Computer simulation analyses might be necessary to ex-
plore these scenarios and other possible ones to identify
cost-effective solutions for better decision making.Conclusion
The performance of HRP-2 test in P. falciparum asymp-
tomatic carriers varied by age and parasite density. This
low sensitivity in screening asymptomatic carriers may
limit its utility in pre-elimination interventional set-
tings. LAMP is a practical and more sensitive test; but
cost may be a barrier to its use as single diagnostic tool
in large-scale MSAT trials. Cost effective combination
of HRP-2 tests and LAMP may be worth exploring.
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